Inolimomab (proposed name, Leukotac) is an immunotherapy monoclonal antibody targeting the interleukin-2 receptor (IL-2) in development for the treatment of acute graft versus host disease (aGVHD).
If you have a Hayes login, click here to view the full report on the Knowledge Center.